AbbVie (ABBV) Revenue (2012 - 2026)

AbbVie (ABBV) has 15 years of Revenue data on file, last reported at $15.0 billion in Q1 2026.

• Revenue for Q1 2026 came in at $15.0 billion, up 12.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.8 billion (up 9.5% YoY), and the FY2025 annual result was $61.2 billion, up 8.57% from the prior year.
• Revenue slipped to $15.0 billion in Q1 2026 per ABBV's latest filing, from $16.6 billion in the prior quarter.
• Over five years, Revenue peaked at $16.6 billion in Q4 2025 and troughed at $12.2 billion in Q1 2023.
• A 5-year average of $14.4 billion and a median of $14.5 billion in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2026: Revenue fell 9.7% in 2023, then gained 12.43% in 2026.
• A 5-year view of Revenue shows it stood at $15.1 billion in 2022, then slipped by 5.42% to $14.3 billion in 2023, then climbed by 5.6% to $15.1 billion in 2024, then rose by 10.04% to $16.6 billion in 2025, then fell by 9.72% to $15.0 billion in 2026.
• Business Quant data shows ABBV's Revenue at $15.0 billion in Q1 2026, $16.6 billion in Q4 2025, and $15.8 billion in Q3 2025.